Loading...
•
Sep 30
Cellectis SA Q3 2025 Earnings Report
Cellectis reported a return to profitability in Q3 2025 with strong revenue growth and improved operating income.
Key Takeaways
Cellectis delivered a profitable Q3 2025, supported by significant revenue from its collaboration with AstraZeneca. The company reported a modest net income and positive operating income, reflecting improved financial health.
Revenue more than doubled YoY to $37.2M, mainly from AZ collaboration.
Net income reached $589K versus a loss of $23.1M in Q3 2024.
EPS turned positive at $0.01 per share.
Operating income came in at $8.04M, a substantial turnaround.
Cellectis SA
Cellectis SA
Cellectis SA Revenue by Geographic Location
Revenue by Geographic Location
France Revenue
CapyFin.com Forward Guidance
Cellectis expects continued momentum into Q4 2025 and 2026, driven by advancing pivotal trials and clinical milestones.
Positive Outlook
- Initiation of pivotal Phase 2 for lasme-cel in Q4 2025
- Strong ORR of 68% and CR/CRi of 56% in BALLI-01 Phase 1
- Positive preliminary efficacy for eti-cel in NHL
- Increased AstraZeneca collaboration revenue
- Continued enrollment in NATHALI-01 study
Challenges Ahead
- Financial losses from derivative-related valuations
- Significant FX-related losses due to USD devaluation
- No GAAP-adjusted EPS reported
- Cash and cash equivalents dropped to $52.2M
- No full-year guidance issued for 2025